Objective
This project focuses on addressing the unique challenges faced by people with type 1 diabetes (T1D), particularly those related to metabolic health, such as weight gain, high blood pressure, and cholesterol problems. Our aim is to explore how these challenges affect long-term health and determine how new treatments might help. To achieve this, we have three main objectives:
1. Understanding Metabolic Challenges in T1D: We will study how common metabolic problems develop in people with T1D, how they change over time, and how they are linked to serious complications like heart disease. By identifying different subgroups of people based on their risk factors, we can better understand who might need more targeted care.
2. Evaluating New Treatments: Some people with T1D are already using medications developed for type 2 diabetes, such as GLP-1 receptor agonists and SGLT-2 inhibitors, even though they are not officially approved for T1D. We will examine how these treatments are being used in real-world settings, assess their effectiveness, and identify any potential risks.
3. Improving Future Care and Research: We will use the insights from our study to improve tools that predict the risk of complications in T1D. These tools will help healthcare providers make more personalised treatment decisions. Additionally, we will generate ideas for future clinical trials that test new therapies tailored to specific groups of people with T1D.
By achieving these objectives, our research will help improve care for people with T1D, providing evidence to support safer and more effective treatments for metabolic challenges in this population.
Background Rationale
Type 1 diabetes (T1D) is a lifelong condition caused by the immune system attacking insulin-producing cells. Managing T1D typically focuses on controlling blood sugar levels with insulin therapy. However, this approach often overlooks other critical health challenges faced by people with T1D, such as obesity, high blood pressure, and abnormal cholesterol. These metabolic problems can lead to long-term complications like heart and kidney disease, but they are not well understood in T1D care.
At the same time, new treatments developed for type 2 diabetes (T2D) have shown great promise. Medications like GLP-1 receptor agonists and SGLT-2 inhibitors not only improve blood sugar control but also reduce the risk of heart and kidney disease. While these treatments may also benefit people with T1D, they are not yet widely recommended due to safety concerns and a lack of robust evidence specific to T1D. For example, the unique challenge of managing T1D—absolute insulin deficiency—may increase risks like diabetic ketoacidosis when using certain medications.
Existing studies exploring metabolic challenges in T1D have significant limitations. Most research is cross-sectional, meaning it captures a snapshot in time rather than tracking changes over the years. This limits our ability to understand how metabolic problems develop and how they influence long-term complications. Additionally, these studies often lack diversity, with limited data on ethnicity and socioeconomic factors. Misclassification of T1D is also a common issue, making it harder to draw reliable conclusions.
These gaps in evidence have slowed progress in addressing metabolic challenges in T1D, leaving patients and healthcare providers without clear guidance on how to use these new treatments safely and effectively.
Our research aims to overcome these challenges by leveraging uniquely detailed, population-wide UK datasets that allow us to track long-term trends, explore the real-world use of new treatments, and ensure accurate identification of people with T1D. By addressing the limitations of previous studies, we will provide the evidence needed to identify who can benefit most from these treatments, when they should be used, and how to use them safely. This research will also help design better clinical trials to test new therapies and improve personalised care for people with T1D.
Description of Project
Type 1 diabetes (T1D) is a lifelong condition that requires careful management to maintain blood sugar levels and prevent complications. However, managing T1D is not just about controlling blood sugar. Many people with T1D also experience metabolic challenges like weight gain, high blood pressure, and abnormal cholesterol levels, which can increase the risk of complications like heart disease. These issues are often overlooked in T1D care, as the focus tends to be on managing blood sugar.
Recent advances in type 2 diabetes (T2D) treatment have introduced new medicines, such as GLP-1 receptor agonists and SGLT-2 inhibitors (and other older medications), which not only help control blood sugar but also reduce the risk of heart and kidney problems. Encouragingly, these medications might also benefit people with T1D. However, they are not currently recommended for T1D in most treatment guidelines. This is partly because the unique features of T1D—such as absolute insulin deficiency—may increase risks when using these medicines. Additionally, research studies have not fully explored how to use these drugs safely and effectively in people with T1D.
Our research aims to fill this gap by studying the unique features of metabolic challenges in people with T1D and determining who might benefit most from these new treatments. To achieve this, we will use three large and detailed UK healthcare datasets: the National Diabetes Audit, the Clinical Practice Research Datalink, and the ADDRESS-2 research cohort. Together, these datasets include information on thousands of people with T1D, including their health outcomes, treatments, and risk factors.
The project has three key objectives:
1. Understanding Metabolic Challenges in T1D: We will track the development of metabolic challenges, such as obesity, high blood pressure, abnormal cholesterol and liver disease in people with T1D over time. By identifying patterns and subgroups with higher risks, we can improve understanding of how these challenges affect long-term health.
2. Evaluating Current Use of New Treatments: Some people with T1D are already using medications like GLP-1 receptor agonists and SGLT-2 inhibitors “off-label” (outside official guidelines). We will assess how these treatments are being used and whether they improve outcomes like blood sugar control and heart health, while also identifying any safety concerns.
3. Improving Future Care: Using insights from our analysis, we will refine tools that help predict the risk of complications in T1D. This will guide healthcare providers in making more personalised treatment decisions and help design future clinical trials to test these therapies in specific patient groups.
This research will provide much-needed evidence to support more tailored and effective care for people with T1D, addressing not only blood sugar control but also the broader metabolic challenges they face. By leveraging the UK’s rich healthcare data, we aim to improve health outcomes and quality of life for people with T1D while paving the way for precision medicine in diabetes care.
Anticipated Outcome
This project aims to improve the care of people living with type 1 diabetes (T1D) by addressing important gaps in how metabolic challenges, like weight gain, high blood pressure, and abnormal cholesterol levels, are managed. These challenges, which significantly increase the risk of heart disease and other complications, are often overlooked in T1D care. By understanding these issues more clearly and exploring how modern diabetes medications might help, this research has the potential to transform the way T1D is treated.
Key outcomes we anticipate include:
1. Improved Understanding of Metabolic Challenges in T1D: We will identify and track patterns of metabolic health issues over time, providing insights into how they develop, progress, and contribute to long-term complications. This will give doctors a better understanding of when and how to address these challenges.
2. Evidence to Support Safer, More Effective Treatments: By studying how new medications, like GLP-1 receptor agonists and SGLT-2 inhibitors, are already being used in real-world T1D care, we will generate evidence on their safety and effectiveness. This will help healthcare providers decide who might benefit most from these treatments and how to use them safely.
3. Personalised Treatment Approaches: Using advanced data analysis, we will identify subgroups of people with T1D who are at the highest risk for complications or who are most likely to benefit from specific therapies. This paves the way for a more personalised approach to T1D care.
4. Better Tools for Risk Prediction: We aim to ultimately refine tools that predict the risk of complications in T1D, incorporating factors like weight, blood sugar variability, and other metabolic markers. These tools will help healthcare providers tailor care to individual patients and make more informed treatment decisions.
5. Foundation for Future Research and Trials: The insights gained will inform the design of clinical trials to test new treatments for specific groups of people with T1D. This will ensure that future therapies are more precisely targeted and relevant to patients' needs.
Ultimately, this research will not only improve our understanding of metabolic health in T1D but also help ensure that people with T1D receive safer, more effective, and more personalised care. By leveraging the UK’s rich healthcare data, we aim to support healthcare providers in making better decisions, improve the quality of life for people with T1D, and lay the groundwork for future advances in diabetes treatment.
Relevance to T1D
Type 1 diabetes (T1D) affects millions of people worldwide, requiring lifelong insulin therapy to manage blood sugar levels. However, many people with T1D also face additional health challenges related to their metabolism, such as weight gain, high blood pressure, and abnormal cholesterol levels. These problems can lead to serious complications, including heart disease, kidney disease, and reduced quality of life. Despite their significant impact, these metabolic issues are often overlooked in T1D care, as the focus remains primarily on blood sugar management.
This research is highly relevant to people with T1D because it addresses critical gaps in understanding and treating these metabolic challenges. The project aims to:
1. Improve Awareness of Metabolic Health in T1D: Many of the complications faced by people with T1D are linked to metabolic dysfunction, yet these issues are often under-recognised in routine care. By studying how these challenges develop and progress, this research will help healthcare providers better understand their importance and take action earlier.
2. Explore New Treatment Options: Medications originally developed for type 2 diabetes (T2D), such as GLP-1 receptor agonists and SGLT-2 inhibitors, show promise for improving metabolic health in T1D. However, these treatments are not yet widely approved for T1D, leaving people without access to potentially beneficial options. This research will evaluate how these drugs are already being used in real-world settings, providing the evidence needed to guide safer, more effective treatment decisions.
3. Personalise T1D Care: People with T1D are not all the same—factors like age, weight, ethnicity, and other health conditions can affect their risks and treatment needs. By identifying subgroups of individuals who are most likely to benefit from specific treatments, this research will pave the way for a more personalised approach to T1D care.
4. Reduce Long-Term Complications: Addressing metabolic challenges in T1D could help prevent serious complications, such as heart disease and kidney failure. By focusing on these issues, this research has the potential to improve both the quality and length of life for people with T1D.
Ultimately, this project aims to transform the way T1D is understood and treated. By shining a light on overlooked aspects of T1D care and exploring innovative treatment options, this research has the potential to make a real difference in the lives of people with T1D, offering them better health outcomes and a brighter future.